Full-Time

Senior Manager

Real Estate, Multiple Teams

Posted on 9/23/2025

Deadline 10/1/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$120.8k - $201.4k/yr

+ Bonus

No H1B Sponsorship

Tampa, FL, USA + 3 more

More locations: Phoenixville, PA, USA | Groton, CT, USA | New York, NY, USA

Hybrid

Work Location Assignment: Hybrid; Standard work schedule & 10% travel required.

Category
Real Estate (1)
Required Skills
Agile
SCRUM
Requirements
  • Degree in Computer Sciences, Information Systems, Engineering, or technology related technical field, or equivalent experience.
  • At least 6-8 years in pharmaceutical and life sciences industry.
  • At least 6-8 years in IT Project Management/Service Lifecycle Management Experience
  • PMP & ITIL Certifications desired
  • Proven capability leading projects in agile environment; Scrum Master or Product Owner certification preferred.
  • Demonstrated experience in managing complex IT projects and transition across single or multiple IT discipline and multiple geographic sites.
  • Knowledge and experience in: Project Management, managing external service providers, ITIL Service Management Lifecycle framework & processes, and IT Financial Management.
  • Ability to manage issues at high and detailed level depending on audience to facilitate smooth project transition to BAU operations.
  • Solid stakeholder management, negotiation, and influence skills.
  • Diplomatic and customer serviced focused; ability to manage key stakeholders in positive, poised, and effective manner.
  • Proven experience in effectively communicating technical issues/challenges with non-technical people.
  • Excellent oral and written communications
  • Language: Bilingual English / Spanish - Proficient
  • Must be self-motivated, must have an ability to work well in a geographically dispersed, virtual team environment, must exhibit a positive and professional attitude, and a strong team player.
Responsibilities
  • Be the Regional point of contact for CTIES Infrastructure project for North America – Midwest, East & Northeast Regions driven from GWE/WRD/PGS Facilities teams.
  • Provide CTIES Infrastructure requirements through each phase of the project and assist in developing timeline based on real estate related activities, business priorities and prioritized portfolio.
  • Own plans and schedule, for real estate initiatives across Digital creation centers from project execution initiation to project closeout.
  • Lead overall Digital coordination and program management of real estate projects, which can include new site buildouts, existing site modifications, and site closures.
  • Accountable for successful delivery of CTIES infrastructure Services for real estate portfolio of projects.
  • Develop holistic regional project portfolio reports for North America – Midwest, East & Northeast Regions.
  • Provide awareness of regional dependencies and/or scheduling conflicts across services or programs.
  • Implement regional program/project status and reporting as ensuring transparency around site dependencies.
  • Ensure key risks and issues are identified, documented, and escalated, if necessary. Owns the resolution of regional scheduling conflicts.
  • Create project plans and ensures upkeep throughout project.
  • Lead Weekly Project calls to ensure alignment on timelines and deliverables and provide meeting summary, actions, and Risk.
  • Provide weekly portfolio updates for all projects in North America – Midwest, East & Northeast Regions.
  • Drive continuous improvement of global processes and patterns which integrate activities & dependencies across CTIES Product/Service Areas for predictable outcomes.
  • Ensure one-time and ongoing project costs are approved prior to project work starting.
  • Mentor and support regional operations team members.
  • Lead Real Estate portfolio reviews as Scrum Master leveraging agile methodologies, including weekly stand-ups, retrospectives, strategic planning, and Quarterly Business Reviews.
  • Lead Process Automation activities, leveraging tools and creating dashboards to facilitate team’s operational efficiency and drive informed decision making.
  • Drive improvements to project planning and execution workflows to ensure work smoothly transitions across CTIES product owners.
Desired Qualifications
  • Good understanding of the specific technology areas and working knowledge across infrastructure components.
  • Demonstrated ability to develop/maintain a deep operational relationship with multiple vendors and holding them accountable for the delivery of various IT service disciplines.
  • Ability to partner with vendors to identify solutions / workarounds / alternatives to business needs or to address problems.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE